Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Palatin Technologies Inc (GB:0KF3)
LSE:0KF3
Holding GB:0KF3?
Track your performance easily
0KF3 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.94 - $5.45
Previous Close$0.94
Volume83.31K
Average Volume (3M)4.21K
Market Cap
$18.61M
Enterprise Value$20.35M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$1.74M
Price to Earnings (P/E)―
Beta-0.11
Next Earnings
Oct 01, 2024EPS Estimate
-$0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.49
Shares Outstanding19,370,000
10 Day Avg. Volume429
30 Day Avg. Volume4,213
Standard Deviation0.30
R-Squared0.03
Alpha-0.00928
Financial Highlights & Ratios
Price to Book (P/B)16.50
Price to Sales (P/S)3.35
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.01
Enterprise Value/Gross Profit4.59
Enterprise Value/Ebitda-0.49
Forecast
1Y Price Target
$17.00Price Target Upside1708.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Palatin Technologies News
PremiumCompany Announcements
Palatin Technologies Secures Growth with Warrant Exercise Deal
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPalatin's combination approach could significantly impact the field, assuming positive clinical data.
Expertise And FoundationPalatin's extensive clinical, regulatory, and commercialization expertise in sexual dysfunction treatment should provide a solid foundation as the company embarks on this new clinical development journey in the field of ED.
Market PotentialED represents a substantial market characterized by significant unmet medical needs among patients who are unresponsive to PDE5 inhibitors.
Bears Say
Clinical TrialsThe PL9643 MELODY-1 Phase 3 trial in dry eye disease failed to reach statistical significance on the co-primary endpoints.
Drug UsageOver two-thirds (68%) of obese patients stop using GLP-1 agonists within the first year due to side effects, particularly at higher doses, and a plateau effect.
EarningsPalatin posted F3Q’24 earnings including EPS of -$0.53 vs. consensus of -$0.45 and our -$0.48 estimate.
---
Options Prices
Currently, No data available
---
Ownership Overview
61.36% Insiders
3.90% Mutual Funds
11.97% Other Institutional Investors
22.78% Public Companies and
Individual Investors
0KF3 FAQ
What was Palatin Technologies Inc’s price range in the past 12 months?
Palatin Technologies Inc lowest share price was $0.94 and its highest was $5.45 in the past 12 months.
What is Palatin Technologies Inc’s market cap?
Currently, no data Available
When is Palatin Technologies Inc’s upcoming earnings report date?
Palatin Technologies Inc’s upcoming earnings report date is Oct 01, 2024 which is in 4 days.
How were Palatin Technologies Inc’s earnings last quarter?
Palatin Technologies Inc released its earnings results on May 15, 2024. The company reported -$0.53 earnings per share for the quarter, missing the consensus estimate of -$0.447 by -$0.083.
Is Palatin Technologies Inc overvalued?
According to Wall Street analysts Palatin Technologies Inc’s price is currently Undervalued.
Does Palatin Technologies Inc pay dividends?
Palatin Technologies Inc does not currently pay dividends.
What is Palatin Technologies Inc’s EPS estimate?
Palatin Technologies Inc’s EPS estimate is -$0.65.
How many shares outstanding does Palatin Technologies Inc have?
Palatin Technologies Inc has 19,369,917 shares outstanding.
What happened to Palatin Technologies Inc’s price movement after its last earnings report?
Palatin Technologies Inc reported an EPS of -$0.53 in its last earnings report, missing expectations of -$0.447. Following the earnings report the stock price went down -6.861%.
Which hedge fund is a major shareholder of Palatin Technologies Inc?
Among the largest hedge funds holding Palatin Technologies Inc’s share is Fortress Investment Group LLC. It holds Palatin Technologies Inc’s shares valued at 686.
---
Palatin Technologies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.00 (1708.51% Upside)
$17.00 (1708.51% Upside)
Blogger Sentiment
Bullish
GB:0KF3 Sentiment 100%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.79%
12-Months-Change
Fundamentals
Return on Equity
-588.69%
Trailing 12-Months
Asset Growth
-55.46%
Trailing 12-Months
Company Description
Palatin Technologies Inc
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.
---
0KF3 Earnings Call
Q3 2024
0:00 / 0:00
---
0KF3 Stock 12 Month Forecast
Average Price Target
$17.00
▲(1708.51% Upside)
Technical Analysis
Palatin Technologies
―
Aclaris Therapeutics
―
Clearside Biomedical
―
Kintara Therapeutics
―
TRACON Pharmaceuticals
―
Best Analysts Covering 0KF3
1 Year
1 Year Success Rate
5/24 ratings generated profit
1 Year Average Return
-33.02%
reiterated a buy rating 4 months ago
Copying Michael Higgins's trades and holding each position for 1 Year would result in 20.83% of your transactions generating a profit, with an average return of -33.02% per trade.
---